Journal
SEMINARS IN LIVER DISEASE
Volume 41, Issue 4, Pages 516-524Publisher
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0041-1731708
Keywords
interleukin-35; chronic hepatitis B; JAK; STAT; Treg; Th17; PD-1
Categories
Funding
- Foundation of Science and Technology, Department of Jilin Province (Jilin, Jilin) [20190101006JH]
- Foundation of Qingyuan People's Hospital (Qingyuan, Guangdong) [20190220]
- Natural Science Foundation of Jilin Province (Changchun, Jilin) [20200201482JC]
Ask authors/readers for more resources
IL-35 is a newly identified cytokine that plays a crucial role in chronic hepatitis B disease, affecting immune mechanisms and controlling inflammation. Its contradictory effects on the development of the disease warrant further research and discussion for potential therapeutic breakthroughs.
Interleukin-35 (IL-35) is a newly identified inhibitory cytokine. It has recently been found to play an extremely important role in chronic hepatitis B disease, which makes it likely to be a target for new therapies for hepatitis B malady. IL-35 modulates a variety of immune mechanisms to cause persistent viral infections, such as affecting the ratio of helper T cells, reducing the activity of cytotoxic T cells, hindering the antigen presentation capacity for dendritic cells, and increasing the transcription level of hepatitis B virus. On the other hand, IL-35 can control the inflammation caused by hepatitis B liver injury. Therefore, to seek a breakthrough in curing hepatitis B disease, the contradictory part of IL-35 in the occurrence and development of this sickness is worthy of further discussion and research. This article will systematically review the biological effects of IL-35 and the specific mechanisms affecting the disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available